Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
Sell
-11,622
Closed -$326K 112
2026
Q1
$326K Buy
+11,622
New +$309K 0.01% 110
2025
Q4
Sell
-12,383
Closed -$316K 169
2025
Q3
$316K Buy
+12,383
New +$306K 0.04% 63
2023
Q1
Sell
-63
Closed -$3.23K 135
2022
Q4
$3.23K Sell
63
-28,554
-100% -$1.37M ﹤0.01% 194
2022
Q3
$1.25M Buy
+28,617
New +$1.39M 0.1% 161
2022
Q2
Sell
-10,713
Closed -$546K 339
2022
Q1
$555K Buy
10,713
+8,042
+301% +$417K 0.02% 248
2021
Q4
$158K Sell
2,671
-4,974
-65% -$246K 0.04% 11
2021
Q3
$329K Buy
+7,645
New +$339K 0.02% 266
2021
Q2
Sell
-479
Closed -$18.6K 294
2021
Q1
$17K Buy
+479
New +$17K ﹤0.01% 232

Other funds holding PFE

QVR's PFE Position: Q2 2026 in Review

QVR sold out of Pfizer (PFE) in Q2 2026, closing a stake of 11,622 shares — an estimated $326K sold.

QVR first reported a position in PFE in Q1 2021 and held it in 8 quarters. The position peaked at $1.25M in Q3 2022. 491 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • QVR reported no remaining Pfizer position as of Q2 2026 after selling out during the quarter.
  • QVR sold 11,622 Pfizer shares in Q2 2026, an estimated $326K.
  • QVR first reported a position in Pfizer in Q1 2021 and held it in 8 quarters.
  • QVR's Pfizer position peaked at $1.25M in Q3 2022.
  • 491 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on QVR's 13F filing for Q2 2026.